# EDGAR Filing Document

**Accession Number:** 0001661998
**File Stem:** 0000000000-25-008032
**Filing Date:** 2025-7
**Character Count:** 3430
**Document Hash:** f0434d43d60e7055427155405533b800
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000000000-25-008032.hdr.sgml**: 20251217

**ACCESSION NUMBER**: 0000000000-25-008032

**CONFORMED SUBMISSION TYPE**: UPLOAD

**PUBLIC DOCUMENT COUNT**: 2

**FILED AS OF DATE**: 20250730

**FILED FOR**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Q32 Bio Inc.
- **CENTRAL INDEX KEY:** 0001661998
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 473468154
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** UPLOAD
- **SEC FILE NUMBER:** 001-38433

**BUSINESS ADDRESS:**
- **STREET 1:** 830 WINTER STREET
- **CITY:** WALTHAM
- **STATE:** MA
- **ZIP:** 02451
- **BUSINESS PHONE:** 781-999-0232

**MAIL ADDRESS:**
- **STREET 1:** 830 WINTER STREET
- **CITY:** WALTHAM
- **STATE:** MA
- **ZIP:** 02451

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Homology Medicines, Inc.
- **DATE OF NAME CHANGE:** 20151228
**PUBLIC REFERENCE ACCESSION NUMBER**: 0000950170-25-036823

## Text-Extract

```

                                                            July 30, 2025

Lee Kalowski
CFO and President
Q32 Bio Inc.
830 Winter Street
Waltham, MA 02451

       Re: Q32 Bio Inc.
           Form 10-K for the year ended December 31, 2024
           Filed March 11, 2025
           File No. 001-38433
Dear Lee Kalowski:

       We have limited our review of your filing to the financial statements
and related
disclosures and have the following comment(s).

       Please respond to this letter within ten business days by providing the
requested
information or advise us as soon as possible when you will respond. If you do
not believe a
comment applies to your facts and circumstances, please tell us why in your
response.

       After reviewing your response to this letter, we may have additional
comments.

Form 10-K for the year ended December 31, 2024
Notes to consolidated financial statements
15. Agreements with Horizon, page F-31

1.     Please tell us and revise your disclosure in future filings to address
the following:
           breakout the $75.1 million contingent consideration between
regulatory and sales
           milestones;
           provide a summary of the regulatory milestones and the related
consideration that
           needs to be achieved;
           disclose the extent to which you are required to repay Horizon the
$55 million
           received under your prior agreements with Horizon or any of the
additional $20
           million if bempikibart does not meet any of the milestones; and
           tell us your expected accounting for the liability if bempikibart
does not achieve
           any of the milestones and if no payments are required.

       In closing, we remind you that the company and its management are
responsible for
 July 30, 2025
Page 2

the accuracy and adequacy of their disclosures, notwithstanding any review,
comments,
action or absence of action by the staff.

       Please contact Sasha Parikh at 202-551-3627 or Kevin Vaughn at
202-551-3494 with
any questions.

                                                          Sincerely,

                                                          Division of
Corporation Finance
                                                          Office of Life
Sciences

```

### Attached PDF Documents

**Attachment 1:** `filename1`

_No text found in this document._